Unknown

Dataset Information

0

Adjuvant chemotherapy following trimodality therapy for esophageal carcinoma-Is the evidence sufficient?

ABSTRACT:

SUBMITTER: Atay SM 

PROVIDER: S-EPMC5723781 | biostudies-literature |

REPOSITORIES: biostudies-literature

Json Xml

Similar Datasets

Unknown Benefit of adjuvant chemotherapy based on lymph node involvement for oesophageal cancer following trimodality therapy.
| S-EPMC6069924 | biostudies-other
Unknown A Phase II Trial of Adjuvant Durvalumab Following Trimodality Therapy for Locally Advanced Esophageal and Gastroesophageal Junction Adenocarcinoma: A Big Ten Cancer Research Consortium Study.
| S-EPMC8484871 | biostudies-literature
Transcriptomics A Phase II Trial of Adjuvant Durvalumab following Trimodality Therapy for Locally Advanced Esophageal and Gastroesophageal Junction Adenocarcinoma: A Big Ten Cancer Research Consortium Study
2021-09-12 | GSE183924 | GEO
Unknown Predictors of postoperative complications after trimodality therapy for esophageal cancer.
| S-EPMC3786201 | biostudies-literature
Unknown Adjuvant chemotherapy with paclitaxel and cisplatin in lymph node-positive thoracic esophageal squamous cell carcinoma.
| S-EPMC5422417 | biostudies-literature
Unknown Trimodality Therapy With or Without Neoadjuvant Chemotherapy for Muscle-Invasive Bladder Cancer.
| S-EPMC8376795 | biostudies-literature
Unknown Postoperative adjuvant chemotherapy versus chemoradiotherapy for node-positive esophageal squamous cell carcinoma: a propensity score-matched analysis.
| S-EPMC7245784 | biostudies-literature
Unknown Preoperative Nomogram to Risk Stratify Patients for the Benefit of Trimodality Therapy in Esophageal Adenocarcinoma.
| S-EPMC5928173 | biostudies-literature
Unknown Adjuvant Therapeutic Modalities Following Three-field Lymph Node Dissection for Stage II/III Esophageal Squamous Cell Carcinoma.
| S-EPMC5559967 | biostudies-other
Unknown Combination Trimodality Therapy Using Vismodegib for Basal Cell Carcinoma of the Face.
| S-EPMC4609426 | biostudies-literature